01:15 PM EDT, 04/25/2024 (MT Newswires) -- Compass Therapeutics ( CMPX ) said Thursday that the US Food and Drug Administration has granted fast-track designation for CTX-009 in combination with paclitaxel to treat patients with metastatic or locally advanced biliary tract cancer.

The designation is intended to help drugs reach patients faster by facilitating the development and expediting the review of drugs with the potential to fill an unmet medical need by treating a serious or life-threatening condition.

Shares of Compass Therapeutics ( CMPX ) were down 4% in recent trading.

Price: 1.42, Change: -0.06, Percent Change: -4.05